Evidence map›Paper›PMID 34239620›Full record

Trial reportDisease markers2021

Serum IL-5 and IFN-

Qiu Zhao, Yanzhi Bi, Huiting Sun, Min Xiao

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Qiu ZhaoDepartment of Oncology, Changzhou Tumor Hospital Affiliated to Soochow University, Changzhou 213000, China.
Yanzhi BiDepartment of Oncology, Changzhou Tumor Hospital Affiliated to Soochow University, Changzhou 213000, China.
Huiting SunChangzhou Second People's Hospital, Changzhou 213000, China.
Min XiaoDepartment of Oncology, Changzhou Tumor Hospital Affiliated to Soochow University, Changzhou 213000, China.ORCID https://orcid.org/0000-0001-6042-0785
Soochow University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBecause responses of patients with cancer to immunotherapy can vary in success, effective biomarkers are urgently needed for predicting clinical response with anti-PD-1 treatment. We aimed to evaluate the IL-5 and IFN-

methodsMetastatic NSCLC and GC patients treated with anti-PD-1 monoclonal antibody were studied. Blood samples were taken before PD-1 McAb treatment, after the first cycle treatment, and during efficacy evaluation. The association between IL-5 and IFN-

resultsIL-5 and IFN-

conclusionsOur results suggested that serum IL-5 and IFN-

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkers, TumorCarcinomaCarcinoma, Non-Small-Cell LungClinical Decision RulesFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsImmunotherapyInterferon-gammaInterleukin-5MaleAntibodies, Monoclonal, HumanizedBiomarkers, TumorImmune Checkpoint InhibitorsInterferon-gammaInterleukin-5spartalizumab

Identifiers

PMID34239620
PMCPMC8235970
OpenAlexW3176797802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.